|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DLEU1 |
Gene summary for DLEU1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DLEU1 | Gene ID | 10301 |
| Gene name | deleted in lymphocytic leukemia 1 | |
| Gene Alias | BCMS | |
| Cytomap | 13q14.2-q14.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10301 | DLEU1 | CCI_1 | Human | Cervix | CC | 1.17e-37 | 2.24e+00 | 0.528 |
| 10301 | DLEU1 | CCI_2 | Human | Cervix | CC | 9.88e-32 | 1.93e+00 | 0.5249 |
| 10301 | DLEU1 | CCI_3 | Human | Cervix | CC | 2.36e-71 | 2.60e+00 | 0.516 |
| 10301 | DLEU1 | CCII_1 | Human | Cervix | CC | 6.26e-21 | 4.82e-01 | 0.3249 |
| 10301 | DLEU1 | T1 | Human | Cervix | CC | 9.42e-07 | 1.69e-01 | 0.0918 |
| 10301 | DLEU1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.06e-68 | 1.04e+00 | 0.0155 |
| 10301 | DLEU1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.13e-19 | 5.41e-01 | -0.1808 |
| 10301 | DLEU1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.21e-18 | 9.65e-01 | 0.0216 |
| 10301 | DLEU1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.55e-51 | 1.48e+00 | -0.0811 |
| 10301 | DLEU1 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.54e-12 | 3.19e-01 | -0.1088 |
| 10301 | DLEU1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.57e-51 | 9.48e-01 | -0.1954 |
| 10301 | DLEU1 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.42e-10 | 5.38e-01 | -0.2602 |
| 10301 | DLEU1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.50e-04 | 5.07e-01 | -0.2196 |
| 10301 | DLEU1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.10e-17 | 5.11e-01 | -0.1207 |
| 10301 | DLEU1 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.66e-34 | 1.02e+00 | -0.1526 |
| 10301 | DLEU1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.38e-32 | 6.86e-01 | -0.1464 |
| 10301 | DLEU1 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.19e-76 | 1.43e+00 | -0.1001 |
| 10301 | DLEU1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.24e-52 | 1.45e+00 | -0.059 |
| 10301 | DLEU1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.03e-15 | 8.64e-01 | -0.1706 |
| 10301 | DLEU1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.67e-10 | 4.41e-01 | -0.2061 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DLEU1 | SNV | Missense_Mutation | novel | c.222N>A | p.Asp74Glu | p.D74E | O43261 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.631) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DLEU1 | insertion | Frame_Shift_Ins | novel | c.220_221insA | p.Asp74GlufsTer2 | p.D74Efs*2 | O43261 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DLEU1 | SNV | Missense_Mutation | novel | c.73N>G | p.Ser25Gly | p.S25G | O43261 | protein_coding | deleterious_low_confidence(0) | benign(0.302) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |